AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy

AMSBIO announces new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.

AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy

All CAR-T cell products from AMSBIO are T cells produced from either a group of donors or from individual donor transduced with CAR (Chimeric antigen receptor) - lentivirus.

These CAR-T cells can target different tumor antigens such CD19, CD133, Her-2, EGFR, VEGFR-2 or mesothelin that are highly over-expressed in tumors. These CAR-T cells can express inducible caspase-9 or other suicide gene to induce CAR-T cell killing for increased safety in case this construct in future will be proposed to use in clinical trials. All CAR-T cell products from AMSBIO can be validated for transduction efficiency, cell killing activity and real time cytotoxicity activity. All CAR-T cells from AMSBIO have negative mock controls: lentivirus-transduced CAR-T cells, no ScFv-transduced CAR-T cells and non-transduced T cells.

In addition to these off-the-shelf CAR-T cell products, AMSBIO offers a growing list of engineered cell lines including CAR-T/NK cells and target cells (GFP-Raji cells) to support custom development in applications including animal studies.

PBMC (Peripheral Blood Mononuclear Cells) from AMSBIO are isolated from blood samples using standard Ficoll-Paque and density gradient centrifugation. These PMBC cells can be used for isolation of T cells (used to generate CAR-T cells) and other cell types.

AMSBIO's new CAR T-cell Expansion Medium is specifically optimized for expansion of CAR T-cells, providing 100-fold greater expansion than normal media. CD28 / CD3 cell activation/expansion beads have been introduced to enable researchers to activate and expand human T cells: CD4+, CD8+ T cells, antigen specific T cells or polyclonal T cells.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2019, July 10). AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy. News-Medical. Retrieved on November 19, 2019 from https://www.news-medical.net/news/20190710/AMSBIO-offers-new-best-in-class-CAR-T-cell-range-for-research-and-immunotherapy.aspx.

  • MLA

    AMS Biotechnology. "AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy". News-Medical. 19 November 2019. <https://www.news-medical.net/news/20190710/AMSBIO-offers-new-best-in-class-CAR-T-cell-range-for-research-and-immunotherapy.aspx>.

  • Chicago

    AMS Biotechnology. "AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy". News-Medical. https://www.news-medical.net/news/20190710/AMSBIO-offers-new-best-in-class-CAR-T-cell-range-for-research-and-immunotherapy.aspx. (accessed November 19, 2019).

  • Harvard

    AMS Biotechnology. 2019. AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy. News-Medical, viewed 19 November 2019, https://www.news-medical.net/news/20190710/AMSBIO-offers-new-best-in-class-CAR-T-cell-range-for-research-and-immunotherapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
AMSBIO offers new Luciferase assay systems to help improve gene reporter assays